Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Impaired meningeal lymphatic vessel development worsens stroke outcome.

Yanev P, Poinsatte K, Hominick D, Khurana N, Zuurbier KR, Berndt M, Plautz EJ, Dellinger MT, Stowe AM.

J Cereb Blood Flow Metab. 2019 Jan 9:271678X18822921. doi: 10.1177/0271678X18822921. [Epub ahead of print]

PMID:
30621519
2.

Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly.

Rodriguez-Laguna L, Agra N, Ibañez K, Oliva-Molina G, Gordo G, Khurana N, Hominick D, Beato M, Colmenero I, Herranz G, Torres Canizalez JM, Rodríguez Pena R, Vallespín E, Martín-Arenas R, Del Pozo Á, Villaverde C, Bustamante A, Ayuso C, Lapunzina P, Lopez-Gutierrez JC, Dellinger MT, Martinez-Glez V.

J Exp Med. 2018 Dec 27. pii: jem.20181353. doi: 10.1084/jem.20181353. [Epub ahead of print]

PMID:
30591517
3.

Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer.

Zhang Y, Kirane A, Huang H, Sorrelle NB, Burrows FJ, Dellinger MT, Brekken RA.

Mol Cancer Res. 2018 Oct 17. pii: molcanres.0427.2018. doi: 10.1158/1541-7786.MCR-18-0427. [Epub ahead of print]

PMID:
30333153
4.

Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions.

Dellinger MT, Witte MH.

Clin Exp Metastasis. 2018 Aug;35(5-6):419-424. doi: 10.1007/s10585-018-9907-9. Epub 2018 May 28.

PMID:
29808352
5.

VEGF-C promotes the development of lymphatics in bone and bone loss.

Hominick D, Silva A, Khurana N, Liu Y, Dechow PC, Feng JQ, Pytowski B, Rutkowski JM, Alitalo K, Dellinger MT.

Elife. 2018 Apr 5;7. pii: e34323. doi: 10.7554/eLife.34323.

6.

Mir-126 is a conserved modulator of lymphatic development.

Kontarakis Z, Rossi A, Ramas S, Dellinger MT, Stainier DYR.

Dev Biol. 2018 May 15;437(2):120-130. doi: 10.1016/j.ydbio.2018.03.006. Epub 2018 Mar 15.

PMID:
29550364
7.

Hyperplasia, de novo lymphangiogenesis, and lymphatic regression in mice with tissue-specific, inducible overexpression of murine VEGF-D.

Lammoglia GM, Van Zandt CE, Galvan DX, Orozco JL, Dellinger MT, Rutkowski JM.

Am J Physiol Heart Circ Physiol. 2016 Aug 1;311(2):H384-94. doi: 10.1152/ajpheart.00208.2016. Epub 2016 Jun 24.

8.

Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.

Regan E, Sibley RC, Cenik BK, Silva A, Girard L, Minna JD, Dellinger MT.

PLoS One. 2016 Mar 7;11(3):e0150963. doi: 10.1371/journal.pone.0150963. eCollection 2016.

9.

Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA.

Cancer Res. 2015 Sep 15;75(18):3699-705. doi: 10.1158/0008-5472.CAN-14-2887-T. Epub 2015 Jul 23.

10.

Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK.

Dbouk HA, Weil LM, Perera GK, Dellinger MT, Pearson G, Brekken RA, Cobb MH.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15999-6004. doi: 10.1073/pnas.1419057111. Epub 2014 Oct 31.

11.

Viewpoints on vessels and vanishing bones in Gorham-Stout disease.

Dellinger MT, Garg N, Olsen BR.

Bone. 2014 Jun;63:47-52. doi: 10.1016/j.bone.2014.02.011. Epub 2014 Feb 26. Review.

12.

Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.

Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, Dellinger MT, Castrillon DH, Brekken RA.

Cancer Res. 2014 Feb 15;74(4):1032-44. doi: 10.1158/0008-5472.CAN-13-2800. Epub 2013 Dec 17.

13.

Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature.

Dellinger MT, Meadows SM, Wynne K, Cleaver O, Brekken RA.

PLoS One. 2013 Sep 2;8(9):e74686. doi: 10.1371/journal.pone.0074686. eCollection 2013.

14.

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, Heguy A, Teruya-Feldstein J, Scaglioni PP.

Cancer Discov. 2013 Apr;3(4):444-57. doi: 10.1158/2159-8290.CD-12-0388. Epub 2013 Jan 28.

15.

Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.

Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N.

Mol Cancer Ther. 2012 Nov;11(11):2473-82. doi: 10.1158/1535-7163.MCT-12-0431. Epub 2012 Aug 28.

16.

Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia.

Witte MH, Dellinger MT, Papendieck CM, Boccardo F.

Clin Exp Metastasis. 2012 Oct;29(7):707-27. doi: 10.1007/s10585-012-9493-1. Epub 2012 Jul 15. Review.

PMID:
22798218
17.

Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.

Dellinger MT, Brekken RA.

PLoS One. 2011;6(12):e28947. doi: 10.1371/journal.pone.0028947. Epub 2011 Dec 12.

18.

Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax.

Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM.

Dev Biol. 2011 Jun 15;354(2):253-66. doi: 10.1016/j.ydbio.2011.04.004. Epub 2011 Apr 16.

19.

Lymphangiogenesis and hemangiogenesis: potential targets for therapy.

Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE.

J Surg Oncol. 2011 May 1;103(6):489-500. doi: 10.1002/jso.21714. Review.

20.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.

21.

Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review.

Dellinger MT, Thome K, Bernas MJ, Erickson RP, Witte MH.

Lymphology. 2008 Sep;41(3):98-102. Review.

PMID:
19013876
22.

Supplemental Content

Loading ...
Support Center